Here are the 10-K annual reports from Tonix Pharmaceuticals Holding Corp. (TNXP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow TNXP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TNXP filings page.
Tonix Pharmaceuticals Holding Corp. is a fully integrated biopharmaceutical company focused on central nervous system disorders, immunology, infectious diseases, and rare diseases. In August 2025 it received FDA approval for TONMYA, a bedtime, non-opioid sublingual cyclobenzaprine tablet for fibromyalgia in adults, and launched it in November 2025.
The company also markets two acute migraine products, Zembrace SymTouch (sumatriptan injection) and Tosymra (sumatriptan nasal spray), and is advancing a broad pipeline including TNX‑102 SL for major depressive disorder and acute stress disorder, TNX‑4800 for Lyme disease prophylaxis, TNX‑1500 for kidney transplant rejection and autoimmune conditions, TNX‑1300 for cocaine intoxication, TNX‑1900 and TNX‑2900 for oxytocin‑based CNS and rare disease indications, TNX‑801 as a live‑virus smallpox/mpox vaccine candidate, and TNX‑4200 and TNX‑4900 for antiviral and neuropathic pain indications.